Nonalcoholic steatohepatitis (NASH) is quickly emerging as one of the most common reasons for both liver cirrhosis and liver transplant in the United States – soon predicted to overtake hepatitis C virus as the predominant etiology.  Currently, there are no FDA-approved medications to treat these disorders.  Hopefully, that will soon change.

Guest Author: Scott Malinowski, PharmD

Music by Good Talk